The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: A randomized phase I trial

American Journal of Tropical Medicine and Hygiene

Volumn 86, Issue 1, 2012, Pages 122-125

  Korth Bradley, Joan M ^a   Parks, Virginia ^a   Chalon, Stephan ^a   Gourley, Ian ^a   Matschke, Kyle ^a   Cailleux, Karine ^a   Fitoussi, Serge ^b   Fleckenstein, Lawrence ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIDECTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FAT INTAKE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MEAL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTINEMATODAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIETARY FATS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; MACROLIDES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84855687515     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2012.11-0415     Document Type: Article

References (12)

1. APOC, 2005. Final communique: eleventh session of the Joint Action Forum. Available at: http://www.who.int/apoc/about/structure/jaf/en/index.html. Accessed November 2, 2010.
2. World Health Organization, 2010. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Available at: http://www.who.int/neglected-diseases/2010report/en/. Accessed November 8, 2010.
3. Basáñez M-G, Boussinesq M, 1999. Population biology of human onchocerciasis. Philos Trans R Soc Lond B Biol Sci 354: 809-826. (Pubitemid 29365629)
4. Plaisier AP, van Oortmarssen GJ, Remme J, Habbema JD, 1991. The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Trop 48: 271-284.
5. Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, Brown KR, Rock D, Chen C-Y, Schwertschlag US, 2003. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 43: 1108-1115. (Pubitemid 37174442)
6. Forrester SG, Prichard RK, Beech RN, 2002. A glutamate-gated chloride channel subunit from Haemonchus contortus: expression in a mammalian cell line, ligand binding, and modulation of anthelmintic binding by glutamate. Biochem Pharmacol 63: 1061-1068. (Pubitemid 34267021)
7. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM, Arena JP, 1994. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371: 707-711. (Pubitemid 24327331)
8. Zulalian J, Stout SJ, daCunha AR, Garces T, Miller P, 1994. Absorption, tissue distribution, metabolism, and excretion of moxidectin in cattle. J Agric Food Chem 42: 381-387.
9. Parks V, Patat A, Mayer P, Fleckenstein L, Weber W, 2004. Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin. Clin Exp Pharmacol Physiol 31: 128.
10. Wu C-Y, Benet LZ, 2005. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22: 11-23. (Pubitemid 40558141)
11. Gershkovich P, Hoffman A, 2007. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 32: 24-32. (Pubitemid 47102188)
12. Chen YC, Hung YP, Fleckenstein L, 2002. Liquid chromatographic assay of moxidectin in human plasma for application to pharmacokinetic studies. J Pharm Biomed Anal 29: 917-926. (Pubitemid 34687008)